|
|
Vaccine Detail
|
Allogeneic GM-CSF-Based Myeloma Cell Vaccine |
| Vaccine Information |
- Vaccine Name: Allogeneic GM-CSF-Based Myeloma Cell Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007223
- Type: DNA vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: GM-CSF
- GM-CSF (human)
gene engineering:
- Type: cell transfection
- Description:
- Detailed Gene Information: Click Here.
- MAGEA3
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- WT1
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- MAGEC1
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Adjuvant:
- Preparation: An MM GVAX is being evaluated in which cells from 2 myeloma cell lines are admixed with K562 cells modified to express GM-CSF (Garfall and Stadtmauer, 2016).
- Description: An allogeneic tumor cell vaccine containing myeloma cancer cells transfected with the granulocyte macrophage-colony-stimulating factor (GM-CSF) gene with potential antineoplastic activity. Upon vaccination, allogeneic GM-CSF-based myeloma cellular vaccine secretes GM-CSF, which may potentiate a tumor-specific cytotoxic T-lymphocyte (CTL) response against myeloma cancer cell-associated antigens. (NCIT_C90540).
|
| Host Response |
|
|
| References |
Garfall and Stadtmauer, 2016: Garfall AL, Stadtmauer EA. Cellular and vaccine immunotherapy for multiple myeloma. Hematology. American Society of Hematology. Education Program. 2016; 2016(1); 521-527. [PubMed: 27913524].
NCIT_C90540: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C90540]
|
|
